Bristol Myers Squibb Company $BMY Stock Holdings Increased by Foresight Capital Management Advisors Inc.

Foresight Capital Management Advisors Inc. increased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 32.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 48,144 shares of the biopharmaceutical company’s stock after purchasing an additional 11,774 shares during the quarter. Foresight Capital Management Advisors Inc.’s holdings in Bristol Myers Squibb were worth $2,774,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Norges Bank purchased a new position in shares of Bristol Myers Squibb during the 4th quarter valued at $1,947,272,000. AQR Capital Management LLC increased its stake in shares of Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after acquiring an additional 16,332,924 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Bristol Myers Squibb by 47.0% during the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after acquiring an additional 7,837,485 shares in the last quarter. Geode Capital Management LLC boosted its position in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after purchasing an additional 6,084,046 shares during the last quarter. Finally, Man Group plc boosted its position in Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after purchasing an additional 5,503,391 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on BMY. Royal Bank Of Canada upped their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. Wells Fargo & Company set a $65.00 price target on Bristol Myers Squibb and gave the company an “equal weight” rating in a report on Friday, July 31st. Bank of America lowered their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday, July 10th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Finally, TD Cowen began coverage on shares of Bristol Myers Squibb in a research note on Wednesday. They issued a “buy” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $66.06.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $64.63 on Friday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.10. The stock’s 50-day moving average is $58.71 and its two-hundred day moving average is $58.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The firm has a market cap of $132.02 billion, a P/E ratio of 14.24, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts anticipate that Bristol Myers Squibb Company will post 6.96 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst upgrades improve sentiment. Argus upgraded BMY to Buy, while Zacks raised the stock to a Rank #2 (Buy), citing improving earnings prospects. These recommendations may attract additional income- and value-oriented investors. Argus Upgrades Bristol Myers Squibb to Buy Bristol Myers Moves to Buy
• Positive Sentiment: Recent earnings exceeded expectations. Bristol Myers Squibb reported quarterly earnings of $2.04 per share versus the $1.60 consensus estimate, while revenue of $12.97 billion surpassed the $11.74 billion forecast. Revenue also grew 5.7% year over year, reinforcing the positive earnings narrative discussed on the company’s earnings call. Bristol Myers Squibb Q2 Earnings Call
• Positive Sentiment: Pipeline and research investments provide longer-term support. BMY is launching a real-world study examining luspatercept use in anemia care, while an expanded partnership with Schrödinger will deploy AI drug-discovery tools across BMS teams. These initiatives could improve evidence generation and help accelerate future medicines. Bristol Myers Squibb Tracks Luspatercept Use Schrödinger and BMS Expand Partnership
• Neutral Sentiment: Broader optimism around potential biotech and pharmaceutical catalysts may support sector sentiment, but the cited drug-development opportunities are not specific to BMY. New Drugs Could Fuel Pharma Stock Gains

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.